COLORADO
Department of Health Care Policy & Financing

Dear Provider,

On November 21, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody COVID-19 therapy casirivimab and imdevimab, administered together.

Additional information regarding the limitations of authorized use can be found on theFact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab.

- When casirivimab and imdevimab doses are provided without charge from the government and administered together, providers should only bill for the administration code (M0243) and should not include any codes for casirivimab or imdevimab on the claim.

- If the procedure code for casirivimab and imdevimab (Q0243) is billed to Health First Colorado (Colorado's Medicaid Program), the line may pay at zero.

Contact Felecia.Gephart@state.co.us with questions or concerns.

Thank you,

Department of Health Care Policy & Financing

Please do not reply to this email; this address is not monitored.

See what's happening on our social sites